Section Arrow
Quote
RAPP.NASDAQ
- Rapport Therapeutics Inc.
Quotes are at least 15-min delayed:2026/09/05 01:06 EDT
Regular Hours
Last
 45.77
-1.88 (-3.95%)
Day High 
48 
Prev. Close
47.65 
1-M High
52.93 
Volume 
279.88K 
Bid
45.7
Ask
62.5
Day Low
45.52 
Open
47.63 
1-M Low
40.69 
Market Cap 
2.29B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 49.44 
20-SMA 48.63 
50-SMA 44.15 
52-W High 52.93 
52-W Low 22.06 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.03/-6.80
Enterprise Value
2.29B
Balance Sheet
Book Value Per Share
8.81
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IMRNImmuron Limited1.8+0.69+62.16%-- 
RXRXRecursion Pharmaceuticals3.63+0.19+5.52%-- 
CMNDClearmind Medicine Inc.1.16-0.54-31.76%-- 
MRNAModerna145.55-3.32-2.23%-- 
RAREUltragenyx Pharmaceutical15.3+0.45+3.03%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.